Detailed data on Biogen’s resurrected Alzheimer’s drug raise more questions than answers
Detailed data on Biogen's resurrected Alzheimer's drug raise more questions than answers.
by Rebecca Robbins and Matthew Herper
Dec 05, 2019
3 minutes
SAN DIEGO — Biogen on Thursday presented detailed data making a case for its resurrected Alzheimer’s drug, arguing that its mixed study results can be explained away by differences in whether patients got the highest dose of the medicine.
But the new data deepen sharp questions about the prospects of the drug and are unlikely to convince skeptics who doubt whether the Food and Drug Administration will be willing to approve it. Biogen’s stock was up 1.75% midday on Thursday after its presentation here at the Alzheimer’s research conference known as CTAD.
The drug, known as aducanumab,
You’re reading a preview, subscribe to read more.
Start your free 30 days